This article is more than 5 years old. Information may no longer be current.

FDA panel recommends for approval VisionCare's implantable telescope for AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SARATOGA, Calif. — The U.S. Food and Drug Administration's Ophthalmic Devices Advisory Panel has unanimously recommended that the FDA approve, with conditions, VisionCare Ophthalmic Technologies' premarket application for its implantable telescope therapy for end-stage age-related macular degeneration, the company announced in a press release.

The panel's specified conditions include mandatory post-approval surveillance and labeling suggestions, the release said.

The implantable telescope is the first medical device recommended by the panel for FDA approval for end-stage AMD. The FDA is not bound to follow the recommendations of its advisory panels, but in most cases it does.